Sonidegib

Name: Sonidegib Drug Interactions
Creator: Dr. Brian Staiger, PharmD, BCPS

12 interactions 1 explained in plain English

Also sold as: Odomzo Odomzo®

About Sonidegib

Sonidegib is used to treat basal cell carcinoma (BCC; a type of skin cancer) in adults with cancer that has come back after surgery or radiation, or in adults that cannot be treated with surgery or radiation. Sonidegib is in a class of medications called hedgehog pathway inhibitors. It works by blocking the action of a… Read the full Sonidegib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Abametapir Asciminib Cyclosporine Injection Cyclosporine Ophthalmic Enasidenib Ketoconazole Topical

12 Major

All (12) Major (12)

Major

Sonidegib Abametapir Explained Increased exposure of CYP3A4 substrate Details Sonidegib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Sonidegib Cyclosporine Injection Atopica Increased sonidegib exposure Details Sonidegib Cyclosporine Ophthalmic Cequa Increased sonidegib exposure Details Sonidegib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Sonidegib Ketoconazole Topical Extina® Foam Increased sonidegib exposure Details Sonidegib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Sonidegib Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Sonidegib Letermovir Injection Prevymis Increased sonidegib exposure Details Sonidegib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Sonidegib Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Sonidegib Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.